2010
DOI: 10.1016/j.freeradbiomed.2010.03.017
|View full text |Cite
|
Sign up to set email alerts
|

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

Abstract: Oxidative stress is a prominent feature of Huntington's disease (HD) due to mitochondrial dysfunction and the ensuing overproduction of reactive oxygen species (ROS). This phenomenon ultimately contributes to cognitive and motor impairment, as well as brain pathology, especially in the striatum. Targeting the transcription of the endogenous antioxidant machinery could be a promising therapeutic approach. The NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway is an important path… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
128
0
1

Year Published

2011
2011
2019
2019

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 156 publications
(135 citation statements)
references
References 76 publications
6
128
0
1
Order By: Relevance
“…In this regard, activation of the NFE2L2 pathway has been reported as being beneficial at decreasing the behavioral abnormalities and brain pathology in a murine model of Huntington disease. 77 …”
Section: Figurementioning
confidence: 99%
“…In this regard, activation of the NFE2L2 pathway has been reported as being beneficial at decreasing the behavioral abnormalities and brain pathology in a murine model of Huntington disease. 77 …”
Section: Figurementioning
confidence: 99%
“…The recent identification of a phenotype in a "glial-only" polyQ-htt mouse calls attention to the fact that the NF-E2-related factor-2 (Nrf2)/antioxidant response element-mediated protective pathway is largely localized to astrocytes [117]. This pathway appears to protect neurons from oxidative stress in HD mouse models [118], highlighting the importance of mRNA cellular localization in all HD mouse models. Notably, there is an absence of alterations in most dopamine pathway-related genes in the D9-N171-98Q mouse.…”
Section: Transcriptional Dysregulationmentioning
confidence: 99%
“…CDDO-MA also improves spatial memory and reduces the number and size of amyloid plaques in the hippocampus in a model of Alzheimer's disease in which mice carry two mutations in the human amyloid precursor protein (Dumont et al, 2009). Compared with CDDO-MA, higher drug levels of CDDO-EA and CDDO-TFEA can be obtained in the brain, and both of these amides prolong survival in transgenic mouse models of Huntington's disease (Stack et al, 2010) and ALS (Neymotin et al, 2011). Even when treatment is delayed until the onset of motor symptoms in G93A SOD1 mice, the SOs slow progression of ALS and extend the lifespan of these mice (Neymotin et al, 2011).…”
mentioning
confidence: 99%